ATE229940T1 - 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren - Google Patents

3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren

Info

Publication number
ATE229940T1
ATE229940T1 AT96934967T AT96934967T ATE229940T1 AT E229940 T1 ATE229940 T1 AT E229940T1 AT 96934967 T AT96934967 T AT 96934967T AT 96934967 T AT96934967 T AT 96934967T AT E229940 T1 ATE229940 T1 AT E229940T1
Authority
AT
Austria
Prior art keywords
indolin
vasopressin
spiro
ligands
derivatives
Prior art date
Application number
AT96934967T
Other languages
German (de)
English (en)
Inventor
Loic Foulon
Georges Garcia
Gal Claudine Serradeil-Le
Gerard Valette
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE229940T1 publication Critical patent/ATE229940T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96934967T 1995-10-24 1996-10-24 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren ATE229940T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512533A FR2740136B1 (fr) 1995-10-24 1995-10-24 Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
PCT/FR1996/001666 WO1997015556A1 (fr) 1995-10-24 1996-10-24 Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine

Publications (1)

Publication Number Publication Date
ATE229940T1 true ATE229940T1 (de) 2003-01-15

Family

ID=9483867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96934967T ATE229940T1 (de) 1995-10-24 1996-10-24 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren

Country Status (30)

Country Link
US (2) US5994350A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0873309B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3274471B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100298925B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1106384C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR004225A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE229940T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU715841B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9611198A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ295585B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69625517T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0873309T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE04433B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2191769T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2740136B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP9900331A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL124002A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN185328B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS1949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY115864A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO310974B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ320352A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL187093B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2167864C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK284546B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199800719T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW474917B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA59345C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1997015556A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA968945B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2775598A1 (fr) * 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
HUP9902376A3 (en) 1999-07-15 2002-11-28 Sanofi Aventis Process for producing n-(1,1-dimethyl)-4-[[s'-ethoxi-4-cis-[2-(4-morpholino)-ethoxi]-2'-oxospiro[cyclohexane-1,3'-[3h]indole]-1'(2'h)yl]-sulfonyl]-3-methoxybenzamide and its salts
HU225150B1 (en) * 1999-07-15 2006-07-28 Sanofi Aventis Novel process for producing 2-methoxy-4-(t-butylaminocarbonyl)-benzenesulfonyl chloride
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US7056910B2 (en) * 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
AU2002247127A1 (en) 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
EP1421064B1 (en) * 2001-07-31 2005-05-11 Sanofi-Aventis Process for the preparation of 3-spiro'cyclohexam-1,3'-'3h!indolin-2'-one! derivatives
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
FR2874920B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one comme ligand des recepteurs de la vasopressine
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
EP1831197A2 (de) * 2004-12-31 2007-09-12 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
MX2009003875A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5570172B2 (ja) * 2008-10-08 2014-08-13 持田製薬株式会社 喫煙による循環機能不全の予防／改善または治療剤
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HUE025938T2 (en) 2008-10-17 2016-05-30 Xenon Pharmaceuticals Inc Spiro oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2733145A1 (en) 2009-10-14 2014-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
PH12012501564A1 (en) 2010-02-26 2019-07-17 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
MD4202C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbometoxi ai spiro[ciclopropan-oxindolilor]
MD4201C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbonitrilici ai spiro[ciclopropan-oxindolilor]
MX382981B (es) * 2013-03-08 2025-03-12 Wockhardt Ltd Proceso para la preparacion de (2s, 5r)-7-oxo-6-sulfooxi-2-[((3r)-piperidin-3-carbonil)carbonil hidrazino]-1,6-diaza-biciclo[3.2.1] -octano.
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
TW474917B (en) 2002-02-01
HK1016596A1 (en) 1999-11-05
KR19990067056A (ko) 1999-08-16
JPH11509232A (ja) 1999-08-17
EE9800151A (et) 1998-12-15
BR9611198A (pt) 1999-04-06
RU2167864C2 (ru) 2001-05-27
ZA968945B (en) 1997-05-29
JP2001302631A (ja) 2001-10-31
JP3274471B2 (ja) 2002-04-15
SK284546B6 (sk) 2005-06-02
EP0873309B1 (fr) 2002-12-18
HUP9900331A2 (hu) 1999-05-28
DE69625517D1 (de) 2003-01-30
FR2740136B1 (fr) 1998-01-09
WO1997015556A1 (fr) 1997-05-01
IL124002A (en) 2002-11-10
DE69625517T2 (de) 2003-09-11
NO981817D0 (no) 1998-04-23
PL187093B1 (pl) 2004-05-31
NZ320352A (en) 2000-01-28
PL326555A1 (en) 1998-09-28
FR2740136A1 (fr) 1997-04-25
CN1202886A (zh) 1998-12-23
ES2191769T3 (es) 2003-09-16
MX9803269A (es) 1998-09-30
UA59345C2 (uk) 2003-09-15
MY115864A (en) 2003-09-30
DK0873309T3 (da) 2003-03-17
TR199800719T2 (xx) 1998-08-21
CN1106384C (zh) 2003-04-23
US6046341A (en) 2000-04-04
IS1949B (is) 2004-10-13
EP0873309A1 (fr) 1998-10-28
AU7308096A (en) 1997-05-15
NO310974B1 (no) 2001-09-24
AR004225A1 (es) 1998-11-04
SK49098A3 (en) 1998-09-09
AU715841B2 (en) 2000-02-10
EE04433B1 (et) 2005-02-15
CZ295585B6 (cs) 2005-08-17
KR100298925B1 (ko) 2001-09-06
US5994350A (en) 1999-11-30
NO981817L (no) 1998-04-23
IS4714A (is) 1998-04-14
CZ126798A3 (cs) 1998-08-12
HUP9900331A3 (en) 1999-11-29
IN185328B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-12-30

Similar Documents

Publication Publication Date Title
ATE229940T1 (de) 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren
ATE205185T1 (de) Benzamid-derivate und deren verwendung als vasopressin-antagonisten
ATE285827T1 (de) Neuartige affinitatsliganden und ihre verwendung
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
NO983023D0 (no) Plagg for personlig beskyttelse
DE69617995D1 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
DE69322118D1 (de) Amino-Thiazolderivate und ihre Anwendung als Fungizide
DE69314347D1 (de) Aldonamide und ihre verwendung als grenzflächenaktive substanzen
FI952803A7 (fi) Bentsatsepinonijohdannaiset
NO940190D0 (no) Anvendelse av x-ketoglutarat
NO931399D0 (no) Anvendelse av naturstein
FI972862A7 (fi) Uudet stafylokinaasijohdannaiset
DE59610382D1 (de) Halogenbenzimidazole und ihre verwendung als mikrobizide
DE69637721D1 (de) Ausfahrbare und zusammenschiebbare elemente und unterschiedliche verwendungen der elemente
DE69418676D1 (de) Deprotonierung von Cyclopentadienylderivate
DE69412083D1 (de) Phenylpyrrolderivate und ihre verwendung als antipsychotika
KR940024162U (ko) 샤워링
KR940003987U (ko) 분말 최루탄
KR970041939U (ko) 부품의 방진체결구조
DE69117310D1 (de) Biphosphorylhydrazine und ihre Anwendung als Pestizide
DE69632064D1 (de) Neue tyrosinkinase-rezeptoren und liganden
KR950007988U (ko) 옷걸이의 보호카바
KR960007555U (ko) 아암레스트 커버의 연장된 도어
KR970034239U (ko) 커버의 결합구조
UA1112S (uk) Мікро-еом широкого призначення

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0873309

Country of ref document: EP